SEC Form 4 · accession 0001209191-19-005373
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Truitt
Officer — Chief Executive Officer · Director
Period of report
Jan 23, 2019
Accepted (ET)
Jan 25, 2019 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $2.18 | Jan 23, 2019 | A | 1,097,000 | A | — | Jan 23, 2029 | Common Stock | 1,097,000 | 1,097,000 | D |
Explanation of responses
- F1This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
Remarks
See Exhibit 24.1, Power of Attorney